TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06361277
Drug: Reference Drug or Test Drug
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Oral, QD for 1 Day, Washout period is more than 7 days after administration
Study: NCT05430230
Drug: Naproxen 500 Mg
Normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen tablets
Study: NCT06554626
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: antifolate antineoplastic drug
Study: NCT05427682
Drug: pyroglutamate rongliflozin capsules
Normalized name: pyroglutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one 50mg capsule on Day 1
Study: NCT06265532
Drug: Placebo for EGCG 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered placebo for EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect.
Study: NCT06265532
Drug: Placebo for EGCG 600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered placebo for EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect.
Study: NCT04569942
Drug: Vasopressor
Normalized name: Vasopressor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cease IV fluid resuscitation. If persisting hypotension and/or hypoperfusion commence a vasopressor infusion (e.g. noradrenaline) and titrate according to local practice to achieve target MAP. The target MAP will be determined by the treating clinician. Reassess at least hourly for up to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Boluses of 250ml of IV fluids are permitted if deemed indicated by the treating clinician.
Study: NCT06471465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: placebo IV
Study: NCT06471465
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: corticosteroids IV
Study: NCT05975073
Drug: IDE397
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered PO
Study: NCT05542303
Drug: ZB001 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Cohort1 (3mg/kg) ZB001 of single IV injection
Study: NCT05542303
Drug: ZB001 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Cohort2 (10mg/kg) ZB001 of single IV injection
Study: NCT05542303
Drug: ZB001 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Cohort3 (20mg/kg) ZB001 of single IV injection
Study: NCT05536726
Drug: 608 Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: 608 160 mg at week 0 + 80 mg Q2W ( 6 cycles) +80 mg Q4W during maintenance period
Study: NCT05536726
Drug: 608 Q4W
Approvals — FDA: no, EMA: no, PMDA: no
Description: 608 160 mg Q4W ( 3 cycles) +160 mg Q8W during maintenance period
Study: NCT05536726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
Study: NCT06705998
Drug: BAR502 single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of BAR 502/placebo will be administered as film-coated tablets, in the morning of Day 1, with 150 mL of water, after an overnight fasting of at least 8 hours.~BAR 502 film-coated tablets are available at dose strengths of 3, 10 and 50mg. A maximum of 4 dose levels are pre-planned (3, 10, 30 and 60mg).
Study: NCT06705998
Drug: Placebo single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching BAR 502 placebo film-coated tablets will be given to 2 out of 8 subjects in each cohort using the same regimen as outlined for the active study treatment
Study: NCT06705998
Drug: BAR502 multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 2 multiple ascending doses selected based on results of study part A will be administered to 2 study cohorts of 10 subjects each. The IMP will be orally administered once a day from Day 1 to Day 14, at 8:00±1 h, for a total of 14 doses.
Study: NCT05183958
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles for combined therapy.
Study: NCT06512818
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules with the same characteristics that Psiguavin intervention but filled with a placebo compound
Study: NCT06712316
Drug: BNT327
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT06707142
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally.
Study: NCT05923281
Drug: K-877 0.2 mg/day (once daily)
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 0.2mg tablet
Study: NCT04539041
Drug: antisense oligonucleotide
Normalized name: Antisense oligonucleotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution of antisense oligonucleotide injected intrathecally (spine tap) at multiple dose levels
Study: NCT04539041
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for each dose level
Study: NCT05923281
Drug: K-877 0.4 mg/day (once daily)
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 0.2mg tablet
Study: NCT05923281
Drug: Placebo (once daily)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT06687967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
Study: NCT06694714
Drug: 0.5 ml lidocaine + epinephrine 1:100,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb
Study: NCT06694714
Drug: 1.0 ml lidocaine + epinephrine 1:100,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb
Study: NCT04794699
Drug: IDE397
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDE397 dosed orally
Study: NCT06712836
Drug: MET097
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET097 is an ultra-long-acting, fully-biased analog of human GLP-1.
Study: NCT06715540
Drug: BCD-261, dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
Study: NCT06715540
Drug: BCD-261, dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
Study: NCT06715540
Drug: BCD-261, dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
Study: NCT06715540
Drug: BCD-261, pre-specified therapeautic dose X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
Study: NCT06715540
Drug: BCD-261, pre-specified therapeautic dose X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes
Study: NCT06715540
Drug: BCD-261, pre-specified therapeautic dose Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes
Study: NCT06677957
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin will be administered together with Digoxin as a drug cocktail as specified for the respective period
Study: NCT06706310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains no active substance.
Study: NCT06706310
Drug: TQA3334 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibit viral replication.
Study: NCT06706310
Drug: Nucleoside (acid) analogs (NAs)
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibit viral replication.
Study: NCT06705088
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A look-alike tablet with no active ingredient.
Study: NCT04750616
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo on the day of surgery and post-surgical days one and two
Study: NCT05632133
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving Ibuprofen 200-400 mg only during migraine attacks.
Study: NCT05359263
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The comparator arm consists of placebo orally once daily
Study: NCT04937894
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efficacy and safety of Tigecycline
Study: NCT05117710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo capsules
Study: NCT05033444
Drug: PRV-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD portion: Eligible participants will be randomized to receive a single ascending dose of PRV-002 on study Day 1. Dose escalation will be conducted in a total of 3 cohorts. Within each cohort, 6 participants will be randomized to receive a single dose of PRV-002. The starting dose, dose increments and dose range to be evaluated are based on available nonclinical data. PRV-002 dose levels in the range of 0.133 to 0.533 mg/kg (based on a 60kg participant) will be investigated.~MAD portion: Eligible participants will be randomized to receive a multiple (one dose per day for 5 consecutive days). Dose escalation will be conducted in a total of 2 cohorts. Within each cohort, 6 participants will be randomized to receive of PRV-002. The starting dose, dose increments and dose range to be evaluated are based on available nonclinical data. PRV-002 dose levels in the range of 0.133 to 0.266 mg/kg (based on a 60kg participant) will be investigated.
Study: NCT05033444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo used is hydroxypropyl beta cyclodextrin (HPβCD)
Study: NCT06045624
Drug: OR-101 (Single ascending dose)
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 150mg, 450mg, 900mg, 1500mg OR-101 in dose escalating manner in cohorts 1-6.
Study: NCT06045624
Drug: OR-101 (Food effect)
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food effect participants (8 subjects in 9 cohorts) will only receive OR-101with a high fat meal prior to administration and subjects in corresponding dose under fasted condition will serve as their reference group
Study: NCT05646797
Drug: ASP2074
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous (IV) infusion
Study: NCT06045624
Drug: OR-101 (Multiple ascending dose)
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 135mg, 270mg, 540mg and 900mg OR-101 in dose escalating manner in cohorts 1-6. Total dosage of cohort 7 and 8 will be decided based on Safety review committe's input where cohort 8 will receive this daily for 7 days
Study: NCT06045624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo across Part A and C of the study
Study: NCT04935879
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug
Study: NCT05783180
Drug: Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sesderma LACTYFERRIN™ Forte (64mg/20ml, TID) and Sesderma ZINC Defense™ (20mg/20ml QD)
Study: NCT05783180
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™ (Placebo)
Study: NCT06715462
Drug: Cymbalta®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cymbalta® caps + N0750 placebo caps + Lyrica placebo caps
Study: NCT06715462
Drug: Lyrica®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyrica® caps + N0750 placebo caps + Cymbalta placebo caps
Study: NCT06716645
Drug: Robitussin Maximum Strength Cough and Chest Congestion DM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan Hydrobromide, United States Pharmacopeia (USP) 20 milligram (mg) and Guaifenesin, USP 400 mg
Study: NCT06716645
Drug: Robitussin Maximum Strength Cough and Chest Congestion DM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan Hydrobromide, USP 20 mg and Guaifenesin, USP 400 mg
Study: NCT06714955
Drug: Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: BGM0504 Administered SC
Study: NCT06714955
Drug: Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: BGM0504 Administered SC
Study: NCT06714955
Drug: Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo Administered SC
Study: NCT06719011
Drug: NNC0174-1213 A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to receive NNC0174-1213 A administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.
Study: NCT06717425
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken once daily
Study: NCT06718686
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug
Study: NCT06717698
Drug: NNC0519-0130
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0519-0130 will be administered subcutaneously.
Study: NCT06717698
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching NNC0519-0130 will be administered subcutaneously.
Study: NCT06717438
Drug: BPN14770
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral administration
Study: NCT06717438
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral administration
Study: NCT06421415
Drug: Allergen Immunotherapy Extract
Normalized name: Allergen immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated as usual. The study is an observation of the long term effect of the treatment
Study: NCT06721091
Drug: VNA-318
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 will consist of administration of VNA-318 at the doses of 5 mg to 180 mg in 5 successive cohorts.~Part 2 will consist of administration of VNA-318 in 3 successive cohorts. The doses will be selected based on safety and tolerability assessments, aw well as the observed PK and PD data from the SAD part.~For each SAD and MAD cohort, a sentinel group of 2 subjects will initially be randomized to receive VNA-318 or placebo (1:1 ratio)~Once PK suggests that the therapeutic dose has been reached in the SAD part, the SAD and MAD parts of the study could be run in parallel
Study: NCT06721091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 (SAD) will consist of administration of matching placebo at the doses of 5 mg to 180 mg in 5 successive cohorts.~Part 2 will consist of administration of matching placebo in 3 successive cohorts. The doses will be selected based on safety and tolerability assessments, aw well as the observed PK and PD data from the SAD part.~For each SAD and MAD cohort, a sentinel group of 2 subjects will initially be randomized to receive VNA-318 or placebo (1:1 ratio)
Study: NCT05838755
Drug: GSK3858279
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3858279 will be administered
Study: NCT06500273
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy for lymphodepletion
Study: NCT05838755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered
Study: NCT06723626
Drug: Metabolic resuscitation agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group will receive intravenous hydrocortisone (200mg every 24 hours), vitamin C (1.5g every 6 hours), and thiamine (200 mg every 12 hours).
Study: NCT06723626
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placebo group will receive intravenous hydrocortisone 200mg every 24 hours.
Study: NCT06722430
Drug: Icalcaprant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT05578456
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 2 starch tablets per day per os
Study: NCT06723691
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen
Study: NCT06723691
Drug: HRS9531
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS9531
Study: NCT06050460
Drug: SA55 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel coronavirus broad-spectrum neutralizing antibody SA55 injection
Study: NCT05243550
Drug: UGN-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
Study: NCT06168708
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gentamicin 80 mg (2ml) /3L of irrigation solution (the first 9 Liters during resection and the first 6 Liters during post-operative irrigation)
Study: NCT06168708
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline (2 ml) on the irrigation solution (placebo)
Study: NCT06512415
Drug: 15 mcg Norepinephrine
Normalized name: norepinephrine 0.15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: The assigned dose (15 mcg) will be diluted with normal saline in a 10-cc syringe.
Study: NCT05937854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one or two encapsulated tablets of placebo po QD
Study: NCT00270543
Drug: Taxotere, Fluorouracil, Leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05682807
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-10 mg/kg/day IV maintenance dose given after 24 h for 2 months.
Study: NCT05682807
Drug: Probiotic Formula
Normalized name: Probiotic Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: probiotics sachets supplementation orally, in the form of lyophilized lactic acid bacteria each Aluminium stick pack contains 100 mg ( Meyer et al., 2020) Probio Tec BB12-Blend 30- IF\* (SANDOZ®.) mixed with 10 ml sterile water and given by Ryle tube once daily until discharge from the unit after clinical and laboratory improvement after two months.
Study: NCT05030623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tab plus Fluoxetine 20 mg capsule
Study: NCT06702553
Drug: Nitric Oxide Gas
Normalized name: Nitric oxide gas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 80 parts per million (ppm) NO during CPB through the oxygenator. After weaning of CPB, test gases will be delivered via inspiration limb of ventilator at a dose range of 40-80 ppm until 6 hours after ICU admission or until extubation after surgery, whichever comes first.
Study: NCT05429723
Drug: HS-10383 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for HS-10383
Study: NCT05299203
Drug: Sapropterin dihydrochloride tablets
Normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: dose escalation phase (BH4) aqueous solution is sprayed onto the skin of all radiotherapy areas, 3 times a day until two weeks after the end of radiotherapy.
Study: NCT06702553
Drug: Standard Care Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive standard care and 80 ppm nitrogen (N2, control group) are added to the gas mixture as control. In the circumstances when the N2 is not applicable, such as when the plasma-chemical NO synthesis device is employed for NO generatiaon and delivery, the device will be connected to the CPB and ventilator circuits, but the synthesis will remain inactive in the control group. Consequently, the circuit will be supplied with air devoid of NO.
Study: NCT06694805
Drug: CAB LA + RPV LA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection administered monthly for first 2 initiation doses then every 2 months.
Study: NCT06694805
Drug: Oral ART
Normalized name: Aquoral Artificial Saliva Protective Oral Spra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medication provided to participants by the site/their regular healthcare professional (HCP) as part of their standard of care (SOC) treatment.
Study: NCT06686576
Drug: CAPEOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase Ⅲ：CAPEOX will be administered
Study: NCT06612970
Drug: HB0056
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB0056 Injection
Study: NCT06612970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06706674
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo administered orally once daily
Study: NCT06706622
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially available saline solution
Study: NCT05262400
Drug: PF-07220060 + PF-07104091 combination dose escalation
Normalized name: Influenza, high-dose, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07104091 and PF-07220060 will be administered orally
Study: NCT06705192
Drug: VES001
Approvals — FDA: no, EMA: no, PMDA: no
Description: VES001 is an oral, blood brain barrier ligand of sortilin.~VES001 will be administered orally as a solid within a gelatine capsule without excipients; the capsule strength will be 180 mg.